SLU-PP-332 vs RAD-140: Exercise Mimetic Peptide vs SARM in Performance Research

Introduction: Exercise Mimetic vs Androgen Modulator

SLU-PP-332 and RAD-140 (Testolone) represent two fundamentally different approaches to performance research. SLU-PP-332 is an ERR? agonist that activates the transcriptional programs normally triggered by exercise — enhancing oxidative metabolism, mitochondrial function, and endurance without androgenic signaling. RAD-140 is a selective androgen receptor modulator (SARM) that directly activates androgen receptors to promote muscle protein synthesis with tissue selectivity.

These compounds couldn’t be more different mechanistically, yet they’re both studied in the context of physical performance. Understanding their distinct mechanisms, evidence bases, and risk profiles is essential for researchers selecting appropriate tools for their specific experimental questions.

SLU-PP-332: The ERR? Exercise Mimetic

SLU-PP-332 activates estrogen-related receptor alpha (ERR?), a nuclear receptor and master regulator of oxidative metabolism in skeletal muscle. ERR? controls the expression of hundreds of genes involved in mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and muscle fiber type determination.

Key Mechanisms

• Mitochondrial biogenesis: Increases mitochondrial density in skeletal muscle, enhancing aerobic capacity
• Fatty acid oxidation: Upregulates enzymes in the ?-oxidation pathway, shifting fuel preference toward fat
• Fiber type switching: Promotes slow-twitch (type I) oxidative fiber characteristics, improving endurance
• Exercise gene program: Activates 100+ genes normally triggered by chronic exercise training
• No androgenic activity: Does not interact with androgen receptors

Preclinical Evidence

In mouse studies, SLU-PP-332 increased treadmill running endurance by approximately 50%, reduced body fat without affecting food intake, and enhanced skeletal muscle oxidative capacity (PMID: 37450089). The compound essentially produced the metabolic adaptations of exercise training without the exercise itself.

RAD-140: The Selective Androgen Receptor Modulator

RAD-140 (Testolone) is a non-steroidal SARM developed by Radius Health that binds androgen receptors with high affinity and tissue selectivity. In preclinical models, it showed an anabolic-to-androgenic ratio exceeding 90:1, meaning strong muscle effects with minimal prostate stimulation.

Key Mechanisms

• Direct AR activation: Binds nuclear androgen receptors in muscle, initiating gene transcription for protein synthesis
• Tissue selectivity: Preferentially activates AR in muscle and bone vs prostate and skin
• Nitrogen retention: Enhances positive nitrogen balance, supporting muscle protein accretion
• Neuroprotection: Preclinical evidence for AR-mediated neuroprotective effects

Preclinical Evidence

RAD-140 demonstrated dose-dependent increases in lean body mass in preclinical primate models, with an anabolic effect on levator ani muscle comparable to testosterone. It showed minimal effects on prostate weight, supporting the tissue-selectivity hypothesis. A Phase 1 clinical trial in breast cancer patients showed it was tolerable, though not designed for performance endpoints.

Mechanism Comparison

Performance Research Evidence

SLU-PP-332: Endurance and Metabolic Performance

SLU-PP-332’s performance benefits center on endurance and metabolic efficiency. The 50% increase in treadmill running time in mice is remarkable and suggests profound remodeling of skeletal muscle oxidative capacity. Key performance-relevant findings:

• Increased maximal running distance and time to exhaustion
• Enhanced fatty acid oxidation during exercise (sparing glycogen)
• Improved mitochondrial density and function
• Shift toward oxidative muscle fiber types (type I/IIa)

For comparison, MOTS-c — another exercise mimetic available from Proxiva Labs — achieves similar metabolic improvements through AMPK activation rather than ERR?. The two compounds target overlapping but distinct exercise-responsive pathways.

RAD-140: Strength and Hypertrophy

RAD-140’s performance relevance lies in muscle mass and strength, not endurance. As a direct androgen receptor agonist, it activates the same anabolic gene programs as testosterone — promoting myofibrillar protein synthesis, satellite cell activation, and positive nitrogen balance. Performance-relevant findings:

• Dose-dependent lean mass increases in primate models
• Levator ani muscle growth comparable to testosterone
• No direct endurance or metabolic enhancement
• Potential strength gains through increased contractile protein content

Body Composition Effects

Both compounds improve body composition but through opposite mechanisms:

SLU-PP-332: Reduces fat through enhanced energy expenditure and fatty acid oxidation. Does not directly increase muscle mass but improves muscle quality (oxidative capacity, mitochondrial density). The net result is a leaner, more metabolically efficient muscle phenotype.

RAD-140: Increases lean mass through direct anabolic signaling. Modest fat reduction occurs indirectly through increased basal metabolic rate from greater muscle mass. The net result is increased muscle size and strength with secondary body composition improvement.

Researchers interested in fat loss specifically should also consider Semaglutide (GLP-1 agonist, 15-17% weight loss in trials), AOD 9604 (GH fragment for direct lipolysis), or 5-Amino-1MQ (NNMT inhibitor for fat cell reprogramming).

Safety Profile Comparison

The safety profiles of these two compounds differ dramatically:

SLU-PP-332 Safety

• No testosterone suppression (does not interact with AR or HPG axis)
• No liver toxicity reported in preclinical studies
• No hormonal disruption of any kind observed
• Metabolic effects appear to be muscle-specific
• Limitation: Only preclinical data available; no human safety studies published

RAD-140 Safety Concerns

• Testosterone suppression: Dose-dependent HPG axis suppression confirmed
• Liver toxicity: Multiple case reports of drug-induced liver injury (DILI) requiring hospitalization (PMID: 32370992)
• HDL reduction: Decreased HDL cholesterol observed (cardiovascular concern)
• Regulatory status: FDA warning letters issued; banned by WADA
• Unknown long-term risks: No Phase III trials completed

The safety contrast is stark: SLU-PP-332 shows a clean preclinical profile with no hormonal or hepatic concerns, while RAD-140 carries documented risks of testosterone suppression, liver injury, and lipid disruption.

Frequently Asked Questions

References

1. Heffernan KS, et al. An ERR agonist drives an exercise program in skeletal muscle. bioRxiv/Science. 2023. PMID: 37450089
2. Miller CP, et al. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. ACS Med Chem Lett. 2011;2(2):124-129. PMID: 24900290
3. Flores JE, et al. Drug-induced liver injury by SARMs. ACG Case Rep J. 2020;7(4):e00370. PMID: 32370992
4. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015;21(3):443-454. PMID: 25738459

About Proxiva Labs: We supply research-grade SLU-PP-332 and MOTS-c exercise mimetics alongside our full range of research peptides. All products are third-party tested for purity.